Figure 8.

Cyclic peptide C25 kills B16-OVA tumor cells by antigen-specific CD8⁺ T cell reaction and FOXP3⁺ Tregs decreased. B16-OVA xenograft mice model was established, cyclic peptide C25 (2 mg/kg/day) was treated for 14 days when the tumor grew to 40–80 mm³. (A) MTT analysis of the effect of cyclic peptide C25 on the proliferation of B16-OVA tumor cells in vitro (n = 5). (B) The tumor volumes of mice (n = 5). The (C and D) CD8⁺ T cells (n = 5) and (E and F) FOXP3⁺ Tregs infiltration (n = 4) in cyclic peptide C25 and control group. (G and H) The ratio of CD8⁺ IFN-γ⁺ T cells in the spleen and draining lymph nodes (n = 4). (I and J) The ratio of CD8⁺ IFN-γ⁺ T cells in the tumors (n = 4). Data are expressed as the mean ± SD and statistical significance between groups was determined by Student's t test: *P < 0.05, **P < 0.01, ^***P < 0.001.